4D Molecular Therapeutics Inc (FDMT)

Currency in USD
5.73
-0.32(-5.29%)
Closed·
Pre Market
5.61-0.12(-2.09%)
·
FDMT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
FDMT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.676.02
52 wk Range
2.2417.41
Key Statistics
Prev. Close
5.73
Open
5.97
Day's Range
5.67-6.02
52 wk Range
2.24-17.41
Volume
832.51K
Average Volume (3m)
1.03M
1-Year Change
-63.03%
Book Value / Share
10.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FDMT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
31.10
Upside
+442.76%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

4D Molecular Therapeutics Inc Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics Inc SWOT Analysis


Gene Therapy Promise
Explore 4D Molecular Therapeutics' innovative approach to treating wet AMD and DME, with Phase 3 trials for 4D-150 set to begin in 2025
Market Dynamics
Delve into the $2 billion wet AMD market opportunity and the challenges of treatment durability that could narrow the addressable patient population
Financial Outlook
Analyst price targets range from $15 to $45, reflecting diverse views on 4DMT's potential amid ongoing R&D investments and negative earnings
Competitive Edge
Learn how 4DMT's clinically validated gene therapy platform positions the company in a crowded field, with potential for expansion beyond ophthalmology
Read full SWOT analysis

Compare FDMT to Peers and Sector

Metrics to compare
FDMT
Peers
Sector
Relationship
P/E Ratio
−1.5x−4.0x−0.5x
PEG Ratio
0.05−0.030.00
Price/Book
0.6x0.9x2.6x
Price / LTM Sales
11,540.9x48.7x3.3x
Upside (Analyst Target)
-108.7%43.5%
Fair Value Upside
Unlock11.4%6.9%Unlock

Analyst Ratings

9 Buy
2 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 31.10
(+442.76% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.86 / -0.86
Revenue / Forecast
14.00K / 529.67K
EPS Revisions
Last 90 days

FDMT Income Statement

People Also Watch

16.26
SRPT
-2.93%
38.47
BMNR
+15.53%
6.850
TRON
-1.37%
0.989
GAME
+13.82%
0.561
WINT
+5.45%

FAQ

What Stock Exchange Does 4D Molecular Trade On?

4D Molecular is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for 4D Molecular?

The stock symbol for 4D Molecular is "FDMT."

What Is the 4D Molecular Market Cap?

As of today, 4D Molecular market cap is 265.44M.

What Is 4D Molecular's Earnings Per Share (TTM)?

The 4D Molecular EPS (TTM) is -3.18.

When Is the Next 4D Molecular Earnings Date?

4D Molecular will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is FDMT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has 4D Molecular Stock Split?

4D Molecular has split 0 times.

How Many Employees Does 4D Molecular Have?

4D Molecular has 227 employees.

What is the current trading status of 4D Molecular (FDMT)?

As of 07 Aug 2025, 4D Molecular (FDMT) is trading at a price of 5.73, with a previous close of 5.73. The stock has fluctuated within a day range of 5.67 to 6.02, while its 52-week range spans from 2.24 to 17.41.

What Is 4D Molecular (FDMT) Price Target According to Analysts?

The average 12-month price target for 4D Molecular is USD31.1, with a high estimate of USD45 and a low estimate of USD10. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +442.76% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.